It doesn't take Tom DeMark at MarketStudies.com to figure out Lilly is running up the chart fast. The moving averages are rock-solid bullish and money is pouring into this equity. One note of caution, once the sugar high of the Affordable Care Act wears off, the health industry may face serious headwinds. Investors should obviously keep a little closer eye on the makeup of Washington next year. The last reported short interest is paltry and without reason to consider it a meaningful influence at only 1.7% of the average trading float.